Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 1354691-97-6
2. Leniolisib Monophosphate
3. Joenja
4. Cdz173-az
5. 3700m1h39q
6. Cdz-173-az
7. Unii-3700m1h39q
8. Leniolisib (phosphate)
9. 1-propanone, 1-((3s)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-, Phosphate (1:1)
10. Cdz-173
11. 1-[(3s)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one;phosphoric Acid
12. 1-((3s)-3-((6-(6-methoxy-5-(trifluoromethyl)pyrimidin-3-yl)-5,6,7,8-tetrahydropyrido(4,3-d)pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one Phosphate
13. 1-[(3s)-3-({6-[6-methoxy-5-(trifluoromethyl)pyrimidin-3-yl]-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl}amino)pyrrolidin-1-yl]propan-1-one Phosphate
14. Joenja (tn)
15. Leniolisib Phosphate [who-dd]
16. Chembl3989909
17. Schembl15789519
18. Chebi:229650
19. Leniolisib Phosphate (jan/usan)
20. Xxedegoaysgnps-zownyotgsa-n
21. Leniolisib Phosphate [usan]
22. Hy-17635a
23. Akos040758719
24. Da-74950
25. Cs-0069337
26. D11159
27. Q27256604
28. (s)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one Phosphate
29. 1-[(3s)-3-({6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl}amino)pyrrolidin-1-yl]propan-1-one Phosphate
30. Phosphoric Acid--1-[(3s)-3-({6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl}amino)pyrrolidin-1-yl]propan-1-one (1/1)
1. Leniolisib
| Molecular Weight | 548.5 g/mol |
|---|---|
| Molecular Formula | C21H28F3N6O6P |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 14 |
| Rotatable Bond Count | 5 |
| Exact Mass | Da |
| Monoisotopic Mass | Da |
| Topological Polar Surface Area | 161 |
| Heavy Atom Count | 37 |
| Formal Charge | 0 |
| Complexity | 703 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Drugs in Development
Details:
Joenja (leniolisib) is an oral small molecule PI3K delta inhibitor, which is currently being evaluated for the treatment of common variable immunodeficiency (CVID) with immune dysregulation.
Lead Product(s): Leniolisib Phosphate
Therapeutic Area: Immunology Brand Name: Joenja
Study Phase: Phase II/ Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 20, 2025
Lead Product(s) : Leniolisib Phosphate
Therapeutic Area : Immunology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharming Group Begins Phase II Leniolisib Trial for CVID Treatment
Details : Joenja (leniolisib) is an oral small molecule PI3K delta inhibitor, which is currently being evaluated for the treatment of common variable immunodeficiency (CVID) with immune dysregulation.
Product Name : Joenja
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 20, 2025
Details:
Joenja (leniolisib) is an oral small molecule PI3K delta inhibitor, which is currently being evaluated for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Lead Product(s): Leniolisib Phosphate
Therapeutic Area: Rare Diseases and Disorders Brand Name: Joenja
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 11, 2024
Lead Product(s) : Leniolisib Phosphate
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharming Announces Positive Topline Data in Pediatric Clinical Trial of Leniolisib
Details : Joenja (leniolisib) is an oral small molecule PI3K delta inhibitor, which is currently being evaluated for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Product Name : Joenja
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 11, 2024
Details:
Joenja (leniolisib) is an oral small molecule PI3K delta inhibitor, which is currently being evaluated for the treatment of primary immunodeficiency disorders.
Lead Product(s): Leniolisib Phosphate
Therapeutic Area: Genetic Disease Brand Name: Joenja
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 10, 2024
Lead Product(s) : Leniolisib Phosphate
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharming Begins Phase II Trial of Leniolisib in Primary Immunodeficiencies
Details : Joenja (leniolisib) is an oral small molecule PI3K delta inhibitor, which is currently being evaluated for the treatment of primary immunodeficiency disorders.
Product Name : Joenja
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 10, 2024
Details:
Joenja (leniolisib) is an oral PI3K delta inhibitor, the first targeted treatment for activated PI3K delta syndrome in patients aged 12 and older, now being developed for children aged 4 to 11.
Lead Product(s): Leniolisib Phosphate
Therapeutic Area: Rare Diseases and Disorders Brand Name: Joenja
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 04, 2024
Lead Product(s) : Leniolisib Phosphate
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharming Announces Completion of Enrollment in Pediatric Clinical Trial of Leniolisib
Details : Joenja (leniolisib) is an oral PI3K delta inhibitor, the first targeted treatment for activated PI3K delta syndrome in patients aged 12 and older, now being developed for children aged 4 to 11.
Product Name : Joenja
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 04, 2024
Details:
Joenja (leniolisib) is an oral small molecule PI3Kẟ inhibitor approved in US as the first and only targeted treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older.
Lead Product(s): Leniolisib Phosphate
Therapeutic Area: Genetic Disease Brand Name: Joenja
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 13, 2023
Lead Product(s) : Leniolisib Phosphate
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Joenja (leniolisib) is an oral small molecule PI3Kẟ inhibitor approved in US as the first and only targeted treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older.
Product Name : Joenja
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 13, 2023
Details:
Leniolisib is an oral small molecule phosphoinositide 3-kinase delta inhibitor approved in the US as the first and only targeted treatment of activated phosphoinositide 3-kinase delta syndrome in adult and pediatric patients 12 years of age and older.
Lead Product(s): Leniolisib Phosphate
Therapeutic Area: Rare Diseases and Disorders Brand Name: Joenja
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 21, 2023
Lead Product(s) : Leniolisib Phosphate
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Leniolisib is an oral small molecule phosphoinositide 3-kinase delta inhibitor approved in the US as the first and only targeted treatment of activated phosphoinositide 3-kinase delta syndrome in adult and pediatric patients 12 years of age and older.
Product Name : Joenja
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 21, 2023
Details:
Joenja (leniolisib) is an oral, selective PI3K-delta inhibitor which inhibits the signalling pathways that lead to increased production of PIP3, hyperactivity of the downstream mTOR/AKT pathway, and to the dysregulation of B and T cells in patients with APDS.
Lead Product(s): Leniolisib Phosphate
Therapeutic Area: Rare Diseases and Disorders Brand Name: Joenja
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 11, 2023
Lead Product(s) : Leniolisib Phosphate
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Joenja (leniolisib) is an oral, selective PI3K-delta inhibitor which inhibits the signalling pathways that lead to increased production of PIP3, hyperactivity of the downstream mTOR/AKT pathway, and to the dysregulation of B and T cells in patients with ...
Product Name : Joenja
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 11, 2023
Details:
Joenja (leniolisib) is an oral, selective PI3K-delta inhibitor which inhibits the signalling pathways that lead to increased production of PIP3, hyperactivity of the downstream mTOR/AKT pathway, and to the dysregulation of B and T cells in patients with APDS.
Lead Product(s): Leniolisib Phosphate
Therapeutic Area: Rare Diseases and Disorders Brand Name: Joenja
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 08, 2023
Lead Product(s) : Leniolisib Phosphate
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Joenja (leniolisib) is an oral, selective PI3K-delta inhibitor which inhibits the signalling pathways that lead to increased production of PIP3, hyperactivity of the downstream mTOR/AKT pathway, and to the dysregulation of B and T cells in patients with ...
Product Name : Joenja
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 08, 2023
Details:
Joenja (leniolisib) is an oral, selective PI3K-delta inhibitor which inhibits the signalling pathways that lead to increased production of PIP3, hyperactivity of the downstream mTOR/AKT pathway, and to the dysregulation of B and T cells in patients with APDS.
Lead Product(s): Leniolisib Phosphate
Therapeutic Area: Rare Diseases and Disorders Brand Name: Joenja
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 28, 2023
Lead Product(s) : Leniolisib Phosphate
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
PANTHERx® Rare Launches Drug for APDS
Details : Joenja (leniolisib) is an oral, selective PI3K-delta inhibitor which inhibits the signalling pathways that lead to increased production of PIP3, hyperactivity of the downstream mTOR/AKT pathway, and to the dysregulation of B and T cells in patients with ...
Product Name : Joenja
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 28, 2023
Details:
Joenja (leniolisib) is an oral, selective PI3K-delta inhibitor which inhibits the signalling pathways that lead to increased production of PIP3, hyperactivity of the downstream mTOR/AKT pathway, and to the dysregulation of B and T cells in patients with APDS.
Lead Product(s): Leniolisib Phosphate
Therapeutic Area: Rare Diseases and Disorders Brand Name: Joenja
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 24, 2023
Lead Product(s) : Leniolisib Phosphate
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharming Announces US FDA Approval of Joenja® (leniolisib) as The First and Only Treatment Indica...
Details : Joenja (leniolisib) is an oral, selective PI3K-delta inhibitor which inhibits the signalling pathways that lead to increased production of PIP3, hyperactivity of the downstream mTOR/AKT pathway, and to the dysregulation of B and T cells in patients with ...
Product Name : Joenja
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 24, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Patents & EXCLUSIVITIES
US Patents
Patent Expiration Date : 2032-02-19
US Patent Number : 8653092
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 217759
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2032-02-19
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
